4.7 • 919 Ratings
🗓️ 20 March 2018
⏱️ ? minutes
This episode is the recording of February's live Q&A. These Q&A sessions take place the second Tuesday of every month. The questions answered in this episode were submitted by listeners of this podcast, both ahead of time and live. I am, once again, joined on this episode by Brendan Mahan.
In this conversation, you will hear several listener questions. This month, a lot of these conversations involved medication. We also talk about employment and recovering from a loss of employment. These Live Q&A's are a great opportunity for you to get your questions answered. The sessions take place on the 2nd Tuesday of every month at 12:30pm. Go to http://erictivers.com/events.
Use my Audible.com affiliate link for your favorite titles:
http://www.audibletrial.com/ADHDreWired
Support the podcast on Patreon
Patreon allows listeners like you to support content creators like me. With a monthly contribution, you can get access to different levels of perks. One perk example is our Patreon-only Adult Study Hall. Learn more at http://patreon.com/adhdrewired
ADHD reWired Facebook Group:
If you would like to join the ADHD reWired secret Facebook group, go to EricTivers.com/community and fill out an application.
Productivity Q&A
Get your ADHD questions answered live! These Q&A sessions take place on the 2nd Tuesday of every month at 12:30pm. Go to http://erictivers.com/events.
Want to be a guest?
Hey! What about you? Do you have a story? Are you a Coach? Are you an ADHD Clinician? If you answered yes to any of these questions and you'd like to be a guest, schedule a pre-interview call here.
Disclaimer: The podcast and artwork embedded on this page are from Eric Tivers, LCSW, ADHD-CCSP, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Eric Tivers, LCSW, ADHD-CCSP and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.